US Patent 8,178,541: Linagliptin Combination Patent Scope, Expiration, Litigation and Generic Risk

US Patent 8,178,541 protects pharmaceutical combinations and treatment methods pairing linagliptin, a DPP-4 inhibitor, with antidiabetic, lipid-lowering, anti-obesity, or antihypertensive agents. The strongest commercial claims are the narrow claims covering linagliptin with metformin, pioglitazone, or a sulfonylurea. The patent does not independently claim linagliptin monotherapy, the linagliptin molecule itself, or every formulation containing linagliptin.

The patent was issued to Boehringer Ingelheim and is associated with linagliptin combination products, including Jentadueto and other linagliptin-containing regimens. Public patent records identify a July 14, 2006 U.S. filing date and a July 14, 2026 expiration date before any applicable patent-term adjustment or extension analysis.[1][2]

What does US Patent 8,178,541 protect?

US 8,178,541 protects two principal subject-matter categories:

Pharmaceutical compositions containing linagliptin or an acceptable salt together with another therapeutic agent.
Methods of treating type 2 diabetes mellitus or obesity by administering linagliptin with another therapeutic agent.

The claimed linagliptin compound is:

1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine.

This is the compound generally known as linagliptin. The claims cover the compound itself in combination, as well as physiologically acceptable salts.

Patent	Core subject matter	Patent holder	U.S. grant date	Stated expiration
US 8,178,541 B2	Linagliptin combinations and combination treatment methods	Boehringer Ingelheim	May 15, 2012	July 14, 2026, subject to applicable term adjustments

The patent should be analyzed separately from patents covering the linagliptin molecule, crystalline forms, manufacturing processes, dosage forms, and specific commercial combinations.

What is the claim structure of US 8,178,541?

The 48 claims form a layered claim set.

Broad composition claims

Claim 1 requires a pharmaceutical composition comprising:

Linagliptin, an enantiomer, mixture, or salt; and
At least one other agent selected from:
- antidiabetic agents;
- lipid-lowering agents;
- anti-obesity agents; or
- drugs for treating high blood pressure.

The use of “comprising” makes the claim open-ended. A product containing linagliptin and metformin may fall within claim 1 even if it also contains additional active ingredients, excipients, or other therapeutic agents.

The claim does not require:

a fixed ratio of linagliptin to the second agent;
a single tablet;
a specific dose;
a particular release profile;
a synergistic effect;
a particular patient population beyond the treatment claims; or
proof that the combination is clinically superior to monotherapy.

Markush claims for therapeutic agents

Claims 2 through 11 narrow claim 1 by identifying therapeutic classes and individual agents.

The most commercially relevant examples are:

Claim group	Combination category	Express examples
Claims 2-5	Antidiabetic agents	Metformin, sulfonylureas, pioglitazone, rosiglitazone, acarbose, voglibose, insulin, GLP-1 agents
Claims 6-9	Lipid-lowering agents	Simvastatin, atorvastatin, bezafibrate, fenofibrate, ezetimibe
Claim 10	Anti-obesity agents	Sibutramine, tetrahydrolipostatin, cannabinoid-1 antagonists, beta-3 agonists
Claim 11	Antihypertensive agents	AII antagonists, ACE inhibitors, diuretics, beta-blockers

The Markush language creates broad theoretical coverage, but enforceability depends on whether the asserted combination is properly supported by the specification and whether the claim satisfies written-description, enablement, novelty, and obviousness requirements.

Which claims are strongest for commercial products?

The narrowest claims generally present the clearest infringement theories because they identify both linagliptin and a specific or commercially established partner.

Linagliptin and metformin

Claims 44 and 45 specifically cover:

a pharmaceutical composition containing linagliptin and metformin; and
a method of treating type 2 diabetes using linagliptin and metformin.

These claims are the most directly relevant to Jentadueto, the fixed-dose linagliptin/metformin product approved by the FDA.[3]

A generic fixed-dose linagliptin/metformin product would face a direct product-claim risk if its composition contains the claimed active ingredients. A generic applicant could attempt to avoid a composition claim by using separate products or separate administration instructions, but claim 45 creates a separate method-of-use issue where the proposed label instructs administration of both agents for type 2 diabetes.

Linagliptin and pioglitazone

Claims 46 and 47 cover linagliptin with pioglitazone in a composition and treatment method. These claims are narrower than the broad antidiabetic Markush claims but could apply to a fixed-dose or co-administered linagliptin/pioglitazone product.

Linagliptin and sulfonylureas

Claims 41, 42, and 48 cover linagliptin administered with a sulfonylurea. Claim 42 specifically identifies pioglitazone as the thiazolidinedione in a related claim set, while claim 48 covers a sulfonylurea treatment combination.

The claim set identifies glibenclamide, tolbutamide, and glimepiride in dependent composition and method claims. The commercial relevance of individual sulfonylurea combinations depends on the proposed generic label and the marketed product configuration.

How broad are the method-of-treatment claims?

Claims 15 through 48 cover administration rather than merely product composition. The method claims require:

a patient in need;
a pharmaceutically effective amount of linagliptin; and
a pharmaceutically effective amount of at least one other therapeutic agent.

The broadest method claims cover type 2 diabetes mellitus or obesity. Later claims narrow the indication to type 2 diabetes mellitus and identify specific co-therapies.

The method claims can apply where the two active ingredients are:

administered in one fixed-dose product;
administered as separate products;
administered simultaneously; or
administered according to a regimen that satisfies the claim language.

The label is central to infringement analysis for an ANDA applicant. A proposed label that instructs use of linagliptin with metformin for type 2 diabetes may create induced-infringement exposure even if the generic manufacturer does not sell a combined tablet.

What formulations are protected by US 8,178,541?

US 8,178,541 is primarily a combination and method patent, not a detailed formulation patent.

The claims do not require:

immediate release;
extended release;
a particular tablet architecture;
a particular excipient;
a defined dissolution profile;
a specific particle size;
a solid dispersion;
a capsule;
an injectable dosage form; or
a specific linagliptin salt or crystalline polymorph.

The composition claims can therefore reach multiple dosage forms if they contain linagliptin and a claimed second therapeutic agent. The absence of detailed formulation limitations makes the composition claims potentially broad, but it also leaves them exposed to validity challenges based on prior-art combination therapy disclosures and written-description issues.

A product-specific formulation patent may provide a separate barrier. For example, a fixed-dose product may be protected by patents directed to stability, tablet layering, controlled release, manufacturing steps, or a particular combination of active pharmaceutical ingredients. Those patents must be analyzed separately from US 8,178,541.

Is US 8,178,541 an Orange Book patent?

US 8,178,541 has been associated with FDA-listed linagliptin combination products and related regulatory protection. Orange Book relevance depends on the product for which the patent is listed and the patent-use code submitted by the NDA holder.[2]

The principal product relationships are:

Product	Active ingredients	Relevance of US 8,178,541
Tradjenta	Linagliptin	Limited because the patent requires another therapeutic agent
Jentadueto	Linagliptin and metformin	Direct relevance to claims 44 and 45
Jentadueto XR	Linagliptin and metformin extended release	Potential relevance depends on the listed patent and use code
Glyxambi	Linagliptin and empagliflozin	Potential relevance under broader combination claims
Trijardy XR	Linagliptin, empagliflozin, and metformin	Potential relevance under broad composition and method claims

Orange Book listing does not establish validity or infringement. It gives the NDA holder a statutory basis to submit patent information and can trigger certification and litigation procedures under the Hatch-Waxman Act.

When does US Patent 8,178,541 lose exclusivity?

The stated patent expiration date is July 14, 2026.[1][2] The practical loss-of-exclusivity date depends on:

any patent-term adjustment;
any patent-term extension;
pediatric exclusivity;
the specific NDA product;
other listed patents covering linagliptin or the combination; and
the timing of FDA approval for an ANDA.

A patent expiration does not automatically produce generic competition if separate patents remain in force. For linagliptin products, the relevant estate may include:

the basic linagliptin compound patent;
combination patents;
crystalline-form patents;
formulation patents;
manufacturing patents; and
product-specific patents for metformin, empagliflozin, or other co-ingredients.

The commercial launch date must therefore be determined on a product-by-product basis.

What Paragraph IV challenges affect linagliptin combinations?

A generic applicant seeking approval before expiration of an Orange Book-listed patent may submit a Paragraph IV certification alleging that the patent is invalid, unenforceable, or not infringed. The NDA holder may then bring an infringement action within 45 days, triggering a statutory 30-month stay of ANDA approval, subject to statutory exceptions and court developments.[4]

For US 8,178,541, the relevant risk scenarios are:

Generic strategy	Main patent issue
Linagliptin monotherapy	The patent is not the principal barrier because the claims require another therapeutic agent
Linagliptin/metformin fixed-dose tablet	Direct risk under claims 44 and 45
Linagliptin plus pioglitazone	Direct risk under claims 46 and 47
Linagliptin plus sulfonylurea	Risk under claims 41 and 48
Linagliptin plus an unrelated cardiovascular agent	Potential risk under claims 1 and 15
Label excluding patented combination use	Possible section viii carve-out issues and induced-infringement risk

A section viii statement may be available where the applicant seeks approval for an unpatented method of use and can remove or omit the patented indication from its labeling. That strategy is difficult where the entire commercial product is a fixed-dose combination covered by a composition claim.

Which companies are challenging the linagliptin patent estate?

Public generic competition has focused on the broader linagliptin estate, including compound and combination patents. Companies active in the U.S. diabetes-generic market have included Teva, Mylan, Sun Pharmaceutical, Zydus, Lupin, Dr. Reddy’s, and Apotex, although the relevant defendant, patent, product, and litigation status must be matched to the individual ANDA.

US 8,178,541 should not be treated as the only patent in any Paragraph IV dispute. An ANDA applicant may challenge several Orange Book patents in one certification package, while the NDA holder may assert only selected patents in litigation.

How strong is the patent estate for US 8,178,541?

Strengths

The patent has several commercially useful characteristics:

It identifies linagliptin by a specific chemical structure.
It covers both compositions and treatment methods.
It includes broad therapeutic classes.
It contains narrow claims directed to metformin and pioglitazone.
The open “comprising” language can capture products with additional ingredients.
The method claims may reach separate administration of the two active ingredients.

Weaknesses

The principal vulnerabilities are:

Combination treatment with DPP-4 inhibitors and standard antidiabetic agents was a predictable development path.
The broad therapeutic Markush groups may face enablement and written-description scrutiny.
The claims cover a wide range of agents with different pharmacology and development status.
The patent does not require a demonstrated synergistic effect.
Several claims contain drafting inconsistencies and typographical defects.
Claim 36 appears to omit “methyl” from the quinazoline substituent, reciting “4-methyl-quinazolin-2-yl” in one place and “4-methyl-quinazolin-2-ylmethyl” elsewhere in the claim set.
Some dependent claims repeat or reorganize earlier limitations without materially narrowing the commercial scope.

The narrow claims directed to actual commercial combinations are stronger infringement assets than the broad claims covering theoretical categories such as MCH-1 antagonists, ABC1 regulators, or phosphoenolpyruvate carboxykinase inhibitors.

Does US 8,178,541 create biosimilar risk?

No. Linagliptin is a small-molecule drug, not a biologic. The relevant competitive pathway is the ANDA pathway for generic drugs, not the biosimilar pathway under the Public Health Service Act.

The principal regulatory mechanisms are:

Paragraph IV certifications;
section viii statements;
30-month stays;
tentative approval;
ANDA approval after patent expiration; and
possible first-filer exclusivity.

How does US 8,178,541 compare with the broader linagliptin estate?

Estate segment	Typical protection	Relevance to generic launch
Basic compound patent	Linagliptin molecule and salts	Central barrier to linagliptin monotherapy
Combination patent	Linagliptin with metformin and other agents	Central barrier to fixed-dose combinations
Formulation patent	Release profile, excipients, tablet design	Product-specific barrier
Crystal or salt patent	Solid form or pharmaceutical salt	May restrict manufacturing or formulation routes
Manufacturing patent	Synthetic intermediates and processes	May require a non-infringing process
Method-of-use patent	Type 2 diabetes or other indications	Label and induced-infringement risk

US 8,178,541 is commercially important for combination products but does not by itself control all linagliptin products. A generic company could potentially launch linagliptin monotherapy after overcoming the compound patent while still facing a separate combination patent for linagliptin/metformin.

What licensing and settlement issues affect the patent?

Boehringer Ingelheim has commercial relationships involving linagliptin products, including the U.S. alliance with Eli Lilly for certain diabetes products. Commercial collaboration does not transfer ownership of US 8,178,541 or eliminate patent rights.

A settlement agreement could establish an authorized generic date, a license entry date, or restrictions on particular products. Such terms are not inferable from the issued claims. Any licensing or settlement analysis must be tied to a specific litigation docket and agreement.

What generic launch scenarios exist?

Scenario 1: Monotherapy launch

A linagliptin-only ANDA does not practice the combination limitations of US 8,178,541. The principal barriers would be the basic linagliptin compound patent and any formulation or salt patents.

Scenario 2: Fixed-dose linagliptin/metformin launch

This is the highest direct exposure under US 8,178,541 because claims 44 and 45 expressly identify the two active ingredients. A Paragraph IV challenge or post-expiration launch would be required unless the applicant designs around the claims.

Scenario 3: Separate linagliptin and metformin products

Separate products may avoid a composition claim requiring both agents in one composition, but the method claims can remain relevant if the proposed labeling instructs combined treatment.

Scenario 4: Carved-out labeling

A generic applicant may attempt to remove patented combination uses where FDA labeling and statutory requirements permit. This strategy is less effective against a composition claim covering the marketed fixed-dose product.

Key Takeaways

US 8,178,541 is a linagliptin combination patent, not the core linagliptin molecule patent.
The patent claims compositions and treatment methods involving linagliptin plus antidiabetic, lipid-lowering, anti-obesity, or antihypertensive agents.
Claims 44 and 45 are the most commercially important claims for linagliptin/metformin products.
Claims 46 and 47 target linagliptin/pioglitazone combinations.
Claims 41 and 48 target linagliptin with sulfonylureas.
The stated expiration date is July 14, 2026, subject to any applicable term adjustment or extension.
The patent can affect fixed-dose products and co-administration labels.
It is relevant to ANDA Paragraph IV strategy, not biosimilar litigation.
A complete freedom-to-operate analysis must include the linagliptin compound, formulation, salt, crystal, manufacturing, and product-specific patent families.
The broad Markush claims have greater validity risk than the narrow claims directed to commercially established combinations.

FAQs

Is US 8,178,541 the main patent for Tradjenta?

No. Tradjenta contains linagliptin alone, while US 8,178,541 generally requires linagliptin plus another therapeutic agent. The basic linagliptin compound patent is more important for Tradjenta monotherapy.

Does US 8,178,541 cover Jentadueto?

Yes, the patent claims specifically cover compositions and methods involving linagliptin and metformin. Claims 44 and 45 are the clearest examples.

Can a generic company sell linagliptin without infringing US 8,178,541?

Potentially, because the patent requires a combination with another therapeutic agent. Separate patents covering linagliptin itself may still prevent launch.

Does the patent cover a linagliptin/metformin co-pack?

It may. Composition claims depend on whether both active ingredients are present in the claimed composition, while method claims may apply to labeled co-administration even when the products are packaged separately.

Is a fixed-dose combination required for infringement?

No. The claims do not uniformly require a single tablet. Composition claims require the claimed actives in a composition, while method claims require administration of effective amounts of linagliptin and another agent.

References

U.S. Patent No. 8,178,541. (2012). Pharmaceutical compositions comprising a DPP-IV inhibitor and an antidiabetic agent. U.S. Patent and Trademark Office.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA, Center for Drug Evaluation and Research.
U.S. Food and Drug Administration. (2012). Jentadueto prescribing information. Boehringer Ingelheim Pharmaceuticals, Inc.
U.S. Food and Drug Administration. (2024). Abbreviated new drug application approvals and patent certifications. FDA, Center for Drug Evaluation and Research.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Germany	102 38 243	Aug 21, 2002
Germany	103 12 353	Mar 20, 2003

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1532149	⤷ Start Trial	C300504	Netherlands	⤷ Start Trial
European Patent Office	1532149	⤷ Start Trial	1190035-4	Sweden	⤷ Start Trial
European Patent Office	1532149	⤷ Start Trial	PA2011013	Lithuania	⤷ Start Trial
European Patent Office	1532149	⤷ Start Trial	C20110018 00046	Estonia	⤷ Start Trial
European Patent Office	1532149	⤷ Start Trial	91889	Luxembourg	⤷ Start Trial
European Patent Office	1532149	⤷ Start Trial	CA 2011 00030	Denmark	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,178,541

Summary for Patent: 8,178,541